a Department of Oncology and Metabolism, University of Sheffield , UK.
Expert Rev Mol Diagn. 2018 Mar;18(3):227-243. doi: 10.1080/14737159.2018.1439382. Epub 2018 Feb 15.
Numerous clinical and pre-clinical studies have provided ample evidence supporting that the tumor microenvironment plays a significant role during breast cancer development, progression and in determining the therapeutic response. Areas covered: This review focuses on the evolving concept of the microenvironment as the critical participant in each step of the multi-stage process of malignant progression. Currently, only a small number of molecules form part of routine molecular diagnostics in breast caner, but microenvironment-derived biomarkers are potential additions to existing predictive and prognostic marker panels. The authors discuss the dependency of the breast tumor cells on different components of the microenvironment for their survival, dissemination, dormancy and establishment in secondary sites to form overt metastasis, as well as the potential as a therapeutic target to improve breast cancer outcome. Expert commentary: Despite the importance in the development of breast cancer, the contribution of the microenvironment is not considered in routine diagnostic testing or informing therapeutic decisions. However, introduction of immunotherapy will increasingly require patient selection based on the stromal composition of the primary breast tumor. Better understanding of the role of specific microenvironment-derived molecules is likely to inform personalized therapy, leading to improved patient outcome.
大量的临床和临床前研究提供了充分的证据,支持肿瘤微环境在乳腺癌的发生、发展以及治疗反应的决定中起着重要作用。
本综述重点介绍了微环境作为恶性进展多阶段过程中每一步骤的关键参与者的概念的发展。目前,只有少数分子成为乳腺癌常规分子诊断的一部分,但微环境衍生的生物标志物是对现有预测和预后标志物组合的潜在补充。作者讨论了乳腺肿瘤细胞对微环境中不同成分的依赖性,以维持其生存、扩散、休眠和在次级部位定植以形成明显转移,以及作为改善乳腺癌预后的治疗靶点的潜力。
尽管在乳腺癌的发展中具有重要意义,但微环境的贡献在常规诊断测试或告知治疗决策中并未得到考虑。然而,免疫疗法的引入将越来越需要根据原发性乳腺癌的基质组成来选择患者。更好地了解特定的微环境衍生分子的作用可能有助于告知个体化治疗,从而改善患者的预后。